Loading...
In 1928, Alexander Fleming discovered penicillin, and by 1945 it was saving thousands of lives in WWII field hospitals. That same year, Fleming warned in his Nobel lecture: bacteria would develop resistance if antibiotics were used carelessly. He was right within four years. By 1950, 40% of hospital Staphylococcus strains resisted penicillin. Doctors switched to methicillin in 1961. MRSA appeared that same year. The pattern was relentless. Each new antibiotic created a selection pressure that rewarded the tiny fraction of bacteria carrying resistance genes. Those survivors multiplied, passing resistance not just to offspring but horizontally to other species through plasmid transfer — a trick unique to bacteria that accelerates the race enormously. By 2000, vancomycin was the 'antibioti...
Popular framing: We just need to invent better antibiotics or be smarter about prescribing.
Structural analysis: Each antibiotic creates selection pressure that rewards the tiny resistant fraction, and horizontal gene transfer accelerates the spread — a reinforcing loop where use breeds resistance breeds more use. Pharmaceutical incentives compound the trap: a $1B drug whose effective life is shorter than its development cycle is a tragedy-of-the-commons asset no firm can afford to invest in. Humanity has to sprint just to hold position, and the slope is against us.
The popular framing locates agency in individuals while the structural problem is a systems-level tragedy of the commons with no market mechanism for correction. This gap matters because it produces interventions (awareness campaigns, prescribing guidelines) targeted at the least leveraged nodes in the system, while high-leverage nodes — agricultural use regulation, antibiotic market restructuring, horizontal gene transfer as an accelerant — receive inadequate attention and political will.
